COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,003 Articles (22,627 medRxiv, 8,376 bioRxiv)

Most recent first Previous |  Page 2025: Articles 20241-20250  | Next

Social patterning and stability of COVID-19 vaccination acceptance in Scotland: Will those most at risk accept a vaccine?
Williams, L., Flowers, P., McLeod, J., Young, D., Rollins, L., CATALYST project team
10.1101/2020.11.19.20234682 — Posted: 2020-11-19
Antibodies to SARS-CoV-2 are associated with protection against reinfection
Lumley, S. F., O'Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., Hoosdally, S., Chand, M., Oxford University Hospitals Staff Testing Group, , Crook, D. W., O'Donnell, A.-M., Conlon, C. P., Pouwels, K. B., Walker, A. S., Peto, T. E., Hopkins, S., Walker, T. M., Jeffery, K., Eyre, D. W.
10.1101/2020.11.18.20234369 — Posted: 2020-11-19 Discussion: Onsite
Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
McCarthy, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarthy, L. R., Bain, W. G., Haidar, G., Duprex, W. P.
10.1101/2020.11.19.389916 — Posted: 2020-11-19 Discussion: Onsite | Offsite
SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients
Gutierrez-Chamorro, L., Riveira-Munoz, E., Barrios, C., Palau, V., Massanella, M., Garcia-Vidal, E., Badia, R., Pedreno, S., Senserrich, J., Rodriguez, E., Clotet, B., Cabrera, C., Mitja, O., Crespo, M., Pascual, J., Riera, M., Ballana, E.
10.1101/2020.11.18.388850 — Posted: 2020-11-19
Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
Mehalko, J., Drew, M., Snead, K., Denson, J.-P., Wall, V., Taylor, T., Sadtler, K., Messing, S., Gillette, W., Esposito, D.
10.1101/2020.11.18.388868 — Posted: 2020-11-18
Long-chain polyphosphates impair SARS-CoV-2 infection and replication: a route for therapy in man
Ferrucci, V., Dae, Y. K., Asadzadeh, F., Marrone, L., Siciliano, R., Cerino, P., Criscuolo, G., Pisano, I., Quarantelli, F., Izzo, B., Fusco, G., Comegna, M., Boccia, A., Viscardi, M., Borriello, G., Brandi, S., Pierri, B. M., Tiberio, C., Atripaldi, L., Paolella, G., Castaldo, G., Pascarella, S., Bianchi, M., Della Monica, R., Chiariotti, L., Yun, K. S., Cheong, J. H., Kim, H. Y., Zollo, M.
10.1101/2020.11.18.388413 — Posted: 2020-11-18 Discussion: Onsite
Universally available herbal teas based on sage and perilla elicit potent antiviral activity against SARS-CoV-2 in vitro
Le-Trilling, V. T. K., Mennerich, D., Schuler, C., Flores-Martinez, Y., Katschinski, B., Dittmer, U., Trilling, M.
10.1101/2020.11.18.388710 — Posted: 2020-11-18
COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system
De Melo, G. D., Lazarini, F., Levallois, S., Hautefort, C., Michel, V., Larrous, F., Verillaud, B., Aparicio, C., Wagner, S., Gheusi, G., Kergoat, L., Kornobis, E., Cokelaer, T., Hervochon, R., Madec, Y., Roze, E., Salmon, D., Bourhy, H., Lecuit, M., Lledo, P.-M.
10.1101/2020.11.18.388819 — Posted: 2020-11-18 Discussion: Onsite | Offsite
The expression of PDCD1 and CD274 in T cells and macrophages correlated positively with COVID-19 severity
Gao, Q., Liu, S., Ding, R., Chen, H., Dong, X., Xie, J., Li, Y., Chen, L., Liu, H., Mu, F.
10.1101/2020.11.17.378992 — Posted: 2020-11-18
An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
Quinlan, B. D., Li, W., Mou, H., Zhang, L., Chang, J., Peng, S., Ojha, A., Tavora, R., Parcells, M. S., Luo, G. G., Li, W., Zhong, G., Choe, H., Farzan, M.
10.1101/2020.11.18.388934 — Posted: 2020-11-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).